112 related articles for article (PubMed ID: 23790245)
1. Meta-analysis of clinical outcomes of intravenous recombinant tissue plasminogen activator for acute ischemic stroke: within 3 hours versus 3-4.5 hours.
Li BH; Ding X; Yin YW; Liu Y; Gao CY; Zhang LL; Li JC
Curr Med Res Opin; 2013 Sep; 29(9):1105-14. PubMed ID: 23790245
[TBL] [Abstract][Full Text] [Related]
2. Comparison of combined venous and arterial thrombolysis with primary arterial therapy using recombinant tissue plasminogen activator in acute ischemic stroke.
Wolfe T; Suarez JI; Tarr RW; Welter E; Landis D; Sunshine JL; Zaidat OO
J Stroke Cerebrovasc Dis; 2008; 17(3):121-8. PubMed ID: 18436152
[TBL] [Abstract][Full Text] [Related]
3. Results of intravenous thrombolysis within 4.5 to 6 hours and updated results within 3 to 4.5 hours of onset of acute ischemic stroke recorded in the Safe Implementation of Treatment in Stroke International Stroke Thrombolysis Register (SITS-ISTR): an observational study.
Ahmed N; Kellert L; Lees KR; Mikulik R; Tatlisumak T; Toni D;
JAMA Neurol; 2013 Jul; 70(7):837-44. PubMed ID: 23689267
[TBL] [Abstract][Full Text] [Related]
4. Thrombolytic therapy for stroke in patients with preexisting cognitive impairment.
Murao K; Leys D; Jacquin A; Kitazono T; Bordet R; Béjot Y; Kimura K; Godefroy O; Wakisaka Y; Moulin S; Ago T; Sibon I; Bombois S; Mas JL; Hénon H; Pasquier F; Giroud M; Cordonnier C; Okada Y;
Neurology; 2014 Jun; 82(23):2048-54. PubMed ID: 24827495
[TBL] [Abstract][Full Text] [Related]
5. A Stroke Registry Data on the Use of Intravenous Recombinant Tissue Plasminogen Activator in Stroke of Unknown Time of Onset.
Balogun IO; Brown A; Bertoni M; Webb T; Hargroves D; Pullicino P
J Stroke Cerebrovasc Dis; 2016 Aug; 25(8):1843-50. PubMed ID: 27132489
[TBL] [Abstract][Full Text] [Related]
6. Symptomatic intracranial hemorrhage following intravenous thrombolysis for acute ischemic stroke: a critical review of case definitions.
Seet RC; Rabinstein AA
Cerebrovasc Dis; 2012; 34(2):106-14. PubMed ID: 22868870
[TBL] [Abstract][Full Text] [Related]
7. The impact of imbalances in baseline stroke severity on outcome in the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study.
Kwiatkowski T; Libman R; Tilley BC; Lewandowski C; Grotta JC; Lyden P; Levine SR; Brott T;
Ann Emerg Med; 2005 Apr; 45(4):377-84. PubMed ID: 15795715
[TBL] [Abstract][Full Text] [Related]
8. Is there a decreased risk of intracerebral hemorrhage and mortality in obese patients treated with intravenous thrombolysis in acute ischemic stroke?
Hassan AE; Chaudhry SA; Jani V; Grigoryan M; Khan AA; Adil MM; Qureshi AI
J Stroke Cerebrovasc Dis; 2013 May; 22(4):545-9. PubMed ID: 23453555
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of intravenous recombinant tissue plasminogen activator administered in the 3- to 4.5-hour window in Korea.
Park TH; Lee JS; Park SS; Ko Y; Lee SJ; Lee KB; Lee J; Kang K; Park JM; Choi JC; Kim DE; Cho YJ; Kim JT; Kim DH; Cha JK; Han MK; Lee J; Oh MS; Yu KH; Lee BC; Bae HJ; Hong KS
J Stroke Cerebrovasc Dis; 2014 Aug; 23(7):1805-12. PubMed ID: 24957314
[TBL] [Abstract][Full Text] [Related]
10. Does mild deficit for patients with stroke justify the use of intravenous tissue plasminogen activator?
Hassan AE; Zacharatos H; Hassanzadeh B; El-Gengaihy A; AlKawi A; Shhadeh A; Kirmani JF
J Stroke Cerebrovasc Dis; 2010 Mar; 19(2):116-20. PubMed ID: 20189087
[TBL] [Abstract][Full Text] [Related]
11. Intravenous thrombolysis for acute ischemic stroke associated to extracranial internal carotid artery occlusion: the ICARO-2 study.
Paciaroni M; Agnelli G; Caso V; Pieroni A; Bovi P; Cappellari M; Zini A; Nichelli P; Inzitari D; Nesi M; Nencini P; Pezzini A; Padovani A; Tassinari T; Orlandi G; Chiti A; Gialdini G; Alberti A; Venti M; Acciarresi M; D'Amore C; Luda E; Tassi R; Martini G; Ferrarese C; Beretta S; Trentini C; Silvestrelli G; Lanari A; Previdi P; Ciccone A; Delodovici ML; Bono G; Galletti G; Marcheselli S; Del Sette M; Traverso E; Riva M; Silvestrini M; Cerqua R; Consoli D; Monaco S; Toni D
Cerebrovasc Dis; 2012; 34(5-6):430-5. PubMed ID: 23207482
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of applied cases of thrombolytic therapy against ultra-acute ischemic stroke. Using the Japanese Standard Stroke Registry Database.
Shiotsuki H; Ogushi Y; Fushimi K; Kobayashi S;
Tokai J Exp Clin Med; 2005 Apr; 30(1):49-62. PubMed ID: 15952299
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of intravenous thrombolytic therapy for acute ischemic stroke with an integrated acute stroke referral network: initial experience of a community-based hospital in a developing country.
Muengtaweepongsa S; Dharmasaroja P; Kummark U
J Stroke Cerebrovasc Dis; 2012 Jan; 21(1):42-6. PubMed ID: 22225863
[TBL] [Abstract][Full Text] [Related]
14. Renal impairment reduces the efficacy of thrombolytic therapy in acute ischemic stroke.
Power A; Epstein D; Cohen D; Bathula R; Devine J; Kar A; Taube D; Duncan N; Ames D
Cerebrovasc Dis; 2013; 35(1):45-52. PubMed ID: 23428996
[TBL] [Abstract][Full Text] [Related]
15. Utilization of intravenous thrombolysis in 3-4.5 hours: analysis of the Minnesota stroke registry.
Tekle WG; Chaudhry SA; Hassan AE; Peacock JM; Lakshminarayan K; Tsai A; Luepker R; Anderson DC; Qureshi AI
Cerebrovasc Dis; 2012; 34(5-6):400-5. PubMed ID: 23221276
[TBL] [Abstract][Full Text] [Related]
16. Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group.
Kwiatkowski TG; Libman RB; Frankel M; Tilley BC; Morgenstern LB; Lu M; Broderick JP; Lewandowski CA; Marler JR; Levine SR; Brott T
N Engl J Med; 1999 Jun; 340(23):1781-7. PubMed ID: 10362821
[TBL] [Abstract][Full Text] [Related]
17. Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan.
Kono S; Deguchi K; Morimoto N; Kurata T; Deguchi S; Yamashita T; Ikeda Y; Matsuura T; Narai H; Omori N; Manabe Y; Yunoki T; Takao Y; Kawata S; Kashihara K; Abe K
J Stroke Cerebrovasc Dis; 2013 Apr; 22(3):190-6. PubMed ID: 21968092
[TBL] [Abstract][Full Text] [Related]
18. Role of tissue plasminogen activator in acute ischemic stroke.
Hatcher MA; Starr JA
Ann Pharmacother; 2011 Mar; 45(3):364-71. PubMed ID: 21386027
[TBL] [Abstract][Full Text] [Related]
19. Wake-up stroke within 3 hours of symptom awareness: imaging and clinical features compared to standard recombinant tissue plasminogen activator treated stroke.
Roveri L; La Gioia S; Ghidinelli C; Anzalone N; De Filippis C; Comi G
J Stroke Cerebrovasc Dis; 2013 Aug; 22(6):703-8. PubMed ID: 22133742
[TBL] [Abstract][Full Text] [Related]
20. Do women benefit more from systemic thrombolysis in acute ischemic stroke? A Serbian experience with thrombolysis in ischemic stroke (SETIS) study.
Jovanović DR; Beslać-Bumbasirević Lj; Budimkić M; Pekmezović T; Zivković M; Kostić VS;
Clin Neurol Neurosurg; 2009 Nov; 111(9):729-32. PubMed ID: 19647928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
